PRESS RELEASE

<< Back

TRACON Pharmaceuticals Announces Upcoming Presentation of Clinical Data on TRC102, a Selective Inhibitor of DNA Base Excision Repair and Chemotherapy Resistance

November 9, 2009

San Diego, CA – November 9, 2009 – TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical data will be presented on TRC102 at the 21st Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The program targets a unique pathway with the potential for broad application to a wide variety of cancer types. TRC102 is currently being studied as an oral agent in combination with pemetrexed (Alimta®) and as an intravenous agent in combination with temozolomide (Temodar®). In this Phase 1 trial, oral TRC102 was dose-escalated in combination with standard dose pemetrexed for patients with advanced cancer. The presentation details are as follows:

Abstract Title: A Phase 1 Study of Oral TRC102 (Methoxyamine Hydrochloride), an Inhibitor of Base-excision Repair, to Potentiate the Therapeutic Effects of Pemetrexed in Patients with Advanced Refractory Cancer
Presenter: Michael Gordon, MD, Premiere Oncology of Arizona
Date and Time: Tuesday Nov 17, 2009, 12:30 PM - 2:30 PM
Session Title: Drug Resistance and Modifiers 2
Session ID: Poster Session B
Abstract Number: B62
Location: Halls C-D, 2nd Floor, Hynes Convention Center, Boston, MA

About TRACON

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth that began dosing in a Phase 1 clinical trial in cancer patients in July, 2007. TRC105 is a monoclonal antibody that binds CD105 (endoglin) to inhibit angiogenesis that began dosing in a Phase 1 clinical trial in cancer patients in January, 2008. TRC102, a small molecule that reverses resistance to chemotherapeutics, began dosing in 2008 in a Phase 1 trial in combination with Temodar® and a Phase 1 trial in combination with Alimta®. Further information about TRACON Pharmaceuticals can be found at www.traconpharma.com.

TRACON Pharmaceuticals Contact:

Delia Alvarez, (858) 550-0780 ext. 232, info@traconpharma.com